Chronic Myeloid Leukemia Treatment Global Market Report 2024

Description

“Chronic Myeloid Leukemia Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The chronic myeloid leukemia treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By End-User: Hospitals; Specialty Clinics; Other End-Users
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Chronic myeloid leukemia (CML) constitutes a form of cancer that exerts its impact on the bone marrow and blood cells. It is characterized by the excessive production of abnormal white blood cells, referred to as granulocytes. The core objective of CML treatment is the management of the disease, alleviation of symptoms, and enhancement of the overall quality of life for patients grappling with this condition.

Treatment options in the domain of chronic myeloid leukemia encompass a range of approaches, including targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplantation. Among these, targeted therapy assumes prominence as a cancer treatment modality focused on specific molecules or pathways integral to the growth and survival of cancer cells. The administration of these treatments can occur through diverse routes, including oral and parenteral methods, and caters to various end-users such as hospitals and specialized clinics, ultimately underscoring the comprehensive nature of CML management.

The chronic myeloid leukemia treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia treatment market statistics, including chronic myeloid leukemia treatment industry global market size, regional shares, competitors with a chronic myeloid leukemia treatment market share, detailed chronic myeloid leukemia treatment market segments, market trends and opportunities and any further data you may need to thrive in the chronic myeloid leukemia treatment industry. This chronic myeloid leukemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic myeloid leukemia treatment market size has grown strongly in recent years. It will grow from $8.58 billion in 2023 to $9.2 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of chronic myeloid leukemia, growing awareness about cancer treatment, government initiatives, growing research and development activities for chronic myeloid leukemia treatments.

The chronic myeloid leukemia treatment market size is expected to see strong growth in the next few years. It will grow to $12.06 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for effective and more tolerable treatments, rising healthcare spending, investments in chronic myeloid leukemia treatments, growing personalized medicine. Major trends in the forecast period include improved diagnosis and screening, innovative treatments for chronic myeloid leukemia, development of targeted therapies, advanced early diagnosis and screening, monitoring technologies.

The rising incidence of myeloid leukemia is poised to drive the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Myeloid leukemia, a form of cancer originating in the bone marrow, affects the cells responsible for producing various blood cell types. The primary objective of chronic myeloid leukemia (CML) treatment is to enhance bone marrow function by addressing the root cause of leukemia, ultimately lowering the risk of complications related to low blood cell counts, reducing the necessity for chemotherapy and transplants, and improving survival rates among individuals with myeloid leukemia. For instance, in January 2023, the American Cancer Society, a US-based voluntary health organization, estimated that there were approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) in adults during the year 2023. Consequently, the escalating incidence of myeloid leukemia serves as a driving force behind the chronic myeloid leukemia (CML) treatment market's growth.

The rising incidence of chromosome abnormalities is expected to be a key driver behind the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Chromosome abnormalities, which encompass structural or numerical irregularities in an individual's chromosomes-critical carriers of genetic information, have a significant impact on patients' prognoses and may necessitate more aggressive treatments, particularly in cases of CML. For instance, based on a study conducted in Saudi Arabia, it was revealed that chromosome abnormalities were present in 39.3% of 59 newborn infants with congenital anomalies, accounting for 2.3% of total neonatal intensive care unit (NICU) admissions, as reported by the National Library of Medicine (NLM), a US-based institution specializing in biomedical informatics and computational health data science research. Consequently, the increasing prevalence of chromosome abnormalities is driving the expansion of the chronic myeloid leukemia (CML) treatment market.

The growth of the chronic myeloid leukemia treatment market is hampered by the significant costs associated with treatment during the forecast period. The elevated expenses related to chronic myeloid leukemia (CML) treatments present a substantial barrier for patients, leading to various adverse consequences. These consequences encompass reduced treatment demand, delayed diagnosis and intervention, financial hardships for patients, increased healthcare outlays, limited accessibility to essential therapies, and an overall diminished quality of life. For instance, as reported by the National Library of Medicine in December 2022, the total care provider cost for treating chronic myeloid leukemia (CML) was $23,014.40 for imatinib and $43,442.69 for nilotinib. Thus, the high treatment costs are impeding the growth of the chronic myeloid leukemia treatment market.

Prominent companies in the chronic myeloid leukemia (CML) treatment market prioritize the development of groundbreaking diagnostic products to maintain their market presence. An illustrative instance of such innovation is found in the actions of Precipio, Inc., a US-based diagnostic company specializing in cancer diagnostics. For instance, in August 2023, Precipio, Inc. introduced the BCR-ABL 2.0 Panel, specifically designed for chronic myeloid leukemia (CML) diagnosis. This advanced panel plays a pivotal role in identifying the BCR-ABL1 gene, which is crucial for diagnosing CML. It stands out as the most sophisticated BCR-ABL panel, distinguished by its comprehensive coverage, streamlined workflow, reduced costs, and the enhanced quality of patient care. Notably, it includes the detection of ABL1 mutations, eliminating the necessity for a secondary round of testing for the BCR-ABL1 gene and providing highly accurate results. This remarkable innovation significantly shapes the landscape of chronic myeloid leukemia (CML) treatment.

In November 2021, Pfizer Inc., a renowned US-based pharmaceutical and biotechnology firm renowned for producing various medications for chronic myeloid leukemia (CML), successfully acquired Trillium Therapeutics Inc. for a significant sum of $2.2 billion. This strategic acquisition by Pfizer is driven by its commitment to expanding and enhancing its oncology portfolio. The newly acquired biologics from Trillium Therapeutics are specifically engineered to empower a patient's innate immune system, enabling it to more effectively identify and eliminate cancer cells. Trillium Therapeutics Inc., on the other hand, is a clinical-stage immuno-oncology company headquartered in Canada, and it is dedicated to advancing therapies tailored for the treatment of chronic myeloid leukemia (CML). This collaboration stands to greatly bolster Pfizer's position in the field of oncology.

Major players in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.

North America was the largest region in the chronic myeloid leukemia treatment market in 2023. The regions covered in chronic myeloid leukemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic myeloid leukemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia treatment market consists of revenues earned by entities by providing diagnosis and staging, medical consultations and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic myeloid leukemia (CML) market also includes sales of imatinib, dasatinib, bosutinib and ponatinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12261

1. Executive Summary

2. Chronic Myeloid Leukemia Treatment Market Characteristics

3. Chronic Myeloid Leukemia Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Chronic Myeloid Leukemia Treatment Market Size and Growth

5.1. Global Chronic Myeloid Leukemia Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Chronic Myeloid Leukemia Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Chronic Myeloid Leukemia Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chronic Myeloid Leukemia Treatment Market Segmentation

6.1. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
6.2. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Other Route of Administrations
6.3. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Speciality Clinics
Other End-Users

7. Chronic Myeloid Leukemia Treatment Market Regional And Country Analysis

7.1. Global Chronic Myeloid Leukemia Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Chronic Myeloid Leukemia Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia Treatment Market

8.1. Asia-Pacific Chronic Myeloid Leukemia Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chronic Myeloid Leukemia Treatment Market

9.1. China Chronic Myeloid Leukemia Treatment Market Overview
9.2. China Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chronic Myeloid Leukemia Treatment Market

10.1. India Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chronic Myeloid Leukemia Treatment Market

11.1. Japan Chronic Myeloid Leukemia Treatment Market Overview
11.2. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chronic Myeloid Leukemia Treatment Market

12.1. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chronic Myeloid Leukemia Treatment Market

13.1. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chronic Myeloid Leukemia Treatment Market

14.1. South Korea Chronic Myeloid Leukemia Treatment Market Overview
14.2. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chronic Myeloid Leukemia Treatment Market

15.1. Western Europe Chronic Myeloid Leukemia Treatment Market Overview
15.2. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chronic Myeloid Leukemia Treatment Market

16.1. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chronic Myeloid Leukemia Treatment Market

17.1. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chronic Myeloid Leukemia Treatment Market

18.1. France Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chronic Myeloid Leukemia Treatment Market

19.1. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chronic Myeloid Leukemia Treatment Market

20.1. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia Treatment Market

21.1. Eastern Europe Chronic Myeloid Leukemia Treatment Market Overview
21.2. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chronic Myeloid Leukemia Treatment Market

22.1. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chronic Myeloid Leukemia Treatment Market

23.1. North America Chronic Myeloid Leukemia Treatment Market Overview
23.2. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chronic Myeloid Leukemia Treatment Market

24.1. USA Chronic Myeloid Leukemia Treatment Market Overview
24.2. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chronic Myeloid Leukemia Treatment Market

25.1. Canada Chronic Myeloid Leukemia Treatment Market Overview
25.2. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chronic Myeloid Leukemia Treatment Market

26.1. South America Chronic Myeloid Leukemia Treatment Market Overview
26.2. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chronic Myeloid Leukemia Treatment Market

27.1. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chronic Myeloid Leukemia Treatment Market

28.1. Middle East Chronic Myeloid Leukemia Treatment Market Overview
28.2. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chronic Myeloid Leukemia Treatment Market

29.1. Africa Chronic Myeloid Leukemia Treatment Market Overview
29.2. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chronic Myeloid Leukemia Treatment Market Competitive Landscape And Company Profiles

30.1. Chronic Myeloid Leukemia Treatment Market Competitive Landscape
30.2. Chronic Myeloid Leukemia Treatment Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson and Johnson Limited
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Chronic Myeloid Leukemia Treatment Market Other Major And Innovative Companies

31.1. Merck and Co. Inc.
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca Plc
31.5. GSK Plc
31.6. Takeda Pharmaceutical Company Limited
31.7. Amgen Inc.
31.8. Boehringer Ingelheim International GmbH
31.9. Teva Pharmaceutical Industries Ltd.
31.10. Astellas Pharma Inc
31.11. Otsuka Holdings Co Ltd.
31.12. Mylan N.V.
31.13. Astellas Pharma Inc.
31.14. Incyte Corporation
31.15. Lupin Limited

32. Global Chronic Myeloid Leukemia Treatment Market Competitive Benchmarking

33. Global Chronic Myeloid Leukemia Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia Treatment Market

35. Chronic Myeloid Leukemia Treatment Market Future Outlook and Potential Analysis

35.1 Chronic Myeloid Leukemia Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Chronic Myeloid Leukemia Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Chronic Myeloid Leukemia Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer